HCV response in patients with end stage renal disease treated with combination pegylated interferon α-2a and ribavirin

Journal of Clinical Gastroenterology

Volumn 43, Issue 5, 2009, Pages 477-481

  Hakim, Wyel ^a   Sheikh, Shehzad ^a   Inayat, Irteza ^a   Caldwell, Cary ^a   Smith, Douglas ^a   Lorber, Marc ^c   Friedman, Amy ^b   Jain, Dhanpat ^b   Bia, Margaret ^a   Formica, Richard ^a   Mehal, Wajahat ^a,d  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NONE   (United States)

Author keywords

Combination therapy; End stage renal disease; Hepatitis C virus; Pegylated interferon; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY FAILURE; LEUKOPENIA; MALAISE; MALE; MYALGIA; OBSERVATIONAL STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 67651108722     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318180803a     Document Type: Article

References (24)

1. Fabrizi F, Martin P, Dixit V, et al. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis. 1998;31: 647-654. (Pubitemid 28158005)
2. Pujol H, Ponce IG, Lema MG, et al. High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. J Clin Microbiol. 1996;34:1633-1636. (Pubitemid 26190387)
3. Bergman S, Accortt N, Turner A, et al. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis. 2005;45:684-689.
4. Crook ED, Penumalee S, Gavini B, et al. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care. 2005;28:2187-2191. (Pubitemid 41242466)
5. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36: 3-10. (Pubitemid 34700756)
6. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. Morb Mor Weekly Rep. 2001; 50:1-43.
7. Bukh J, Wantzin P, Krogsgaard K, et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. J Infect Dis. 1993;168: 1343-1348. (Pubitemid 23344889)
8. Nakayama E, Akiba T, Marumo F, et al. Prognosis of antihepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11:1896-1902. (Pubitemid 30770525)
9. Sterling RK, Sanyal AJ, Luketic VA, et al. Chronic hepatitis C infection in patients with end stage disease characterization of liver histology and viral load in patients awaiting transplantation. Am J Gastroenterol. 1999;94:3576-3582.
10. Izopet J, Rostaing L, Sandres K, et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infec Dis. 2000;181:852-858. (Pubitemid 30194465)
11. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257-263. (Pubitemid 29024011)
12. Crook ED, Penumalee S, Gavini B, et al. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Am J Transplant. 2005;5:2433-2440.
13. Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation. 1998;66: 471-476. (Pubitemid 28415373)
14. Morales J, Campo C, Castellano G, et al. Impact of hepatitis C in long functioning renal transplant: a clinicopathological followup. Transplant Proc. 1993;25:1450. (Pubitemid 23079057)
15. Periera B, Wright T, Schmid C, et al. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation. 1995;60:799.
16. Kokoglu OF, Ucmak H, Hosoglu S, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006;21:575-580.
17. Tan AC, Brouwer JT, Leusen RV, et al. Safety of interferon and Ribavirin in dialysis patients with chronic hepatitis C: results of a pilot study. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases; Dallas, TX, November 5-9, 1999, Abstract 813.
18. Bruchfeld A, Lindahl K, Reichard O, et al. Pegylated interferon and ribavirin in hemodialysis patients. Nephrol Dial Transplant. 2006;21:1444-1445.
19. Mousa DH, Abdalla AH, Al-Shoail G, et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc. 2004;36:1831-1834. (Pubitemid 39200440)
20. Lamb MW, Marks MI, Wynohradnyk L, et al. 40KD Peginterferon Alfa 2a (Pegasys) can be administered safely in patients with end-stage renal disease. Poster presentation AASLD Annual Meeting. 2001.
21. Bruchfeld A, Stahle L, Andersson J, et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection- a pilot study. J Viral Hep. 2001;8:287-292. (Pubitemid 32673741)
22. Rocha CM, Perez RM, Ferreira AP, et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int. 2006;26:305-310. (Pubitemid 43349320)
23. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology. 2008;47:43-50. (Pubitemid 351171040)
24. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology. 2007;46: 1671-1674.